Page last updated: 2024-09-04

cyc 202 and Adenoma

cyc 202 has been researched along with Adenoma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R	1
Reincke, M; Theodoropoulou, M	1
Araki, T; Ben-Shlomo, A; Cuevas-Ramos, D; Hong, J; Liu, NA; Melmed, S; Tone, M; Tone, Y	1

Reviews

2 review(s) available for cyc 202 and Adenoma

Article	Year
Advances in the medical treatment of Cushing's syndrome. The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:4 Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cabergoline; Cushing Syndrome; Dopamine Agonists; ErbB Receptors; Gefitinib; Hormones; Humans; Imidazoles; Isoquinolines; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Pyrazoles; Pyridines; Receptors, Glucocorticoid; Roscovitine; Somatostatin; Temozolomide; Tretinoin	2019
Tumor-Directed Therapeutic Targets in Cushing Disease. The Journal of clinical endocrinology and metabolism, 2019, 03-01, Volume: 104, Issue:3 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Clinical Trials as Topic; Corticotrophs; Humans; Pituitary ACTH Hypersecretion; Roscovitine; Silybin; Somatostatin; Treatment Outcome; Tretinoin	2019

Article

Year

Advances in the medical treatment of Cushing's syndrome.

The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:4

Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cabergoline; Cushing Syndrome; Dopamine Agonists; ErbB Receptors; Gefitinib; Hormones; Humans; Imidazoles; Isoquinolines; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Pyrazoles; Pyridines; Receptors, Glucocorticoid; Roscovitine; Somatostatin; Temozolomide; Tretinoin

2019

Tumor-Directed Therapeutic Targets in Cushing Disease.

The Journal of clinical endocrinology and metabolism, 2019, 03-01, Volume: 104, Issue:3

Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Clinical Trials as Topic; Corticotrophs; Humans; Pituitary ACTH Hypersecretion; Roscovitine; Silybin; Somatostatin; Treatment Outcome; Tretinoin

2019

Other Studies

1 other study(ies) available for cyc 202 and Adenoma

Article	Year
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:7 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents; Cyclin E; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Primary Cell Culture; Pro-Opiomelanocortin; Purines; Roscovitine; Tumor Cells, Cultured; Young Adult	2015

Article

Year

Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.

The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:7

Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents; Cyclin E; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Primary Cell Culture; Pro-Opiomelanocortin; Purines; Roscovitine; Tumor Cells, Cultured; Young Adult

2015